The US is authorising new Covid-19 antibody tests faster than it is checking their accuracy.
Abbott’s coronavirus RNA test can ID NOW – but maybe not definitively.
A week after one Bristol-Myers Squibb approval decision was delayed a second suffers a similar fate, and the group’s CVR slowly unravels.
Antigen tests are faster and cheaper than viral RNA assays, but are notably less accurate.
As the battle between Parp inhibitors for front-line ovarian cancer intensifies, biomarker testing and Avastin biosimilars will play a role.
Robust specificity data mark Roche’s serological test out as a major competitor.
Cellex wins the race to get the FDA’s buy-in for a blood test to pinpoint immunity.
As a Covid-19 vaccine exclusivity and senior management storm engulfs Curevac, the German mRNA specialist insists it’s just conjecture and coincidence.
The FDA is loosening its rules on the authorisation of diagnostic tests for the new coronavirus, but it is still some way behind Europe.